Evidence map›Paper›PMID 39331815›Full record

ArticleEmerging microbes & infections2024

A platform for the rapid screening of equine immunoglobins F (ab)2 derived from single equine memory B cells able to cross-neutralize to influenza virus.

Yuezhi Lin, Yayu Wang, Hongxin Li, Tong Liu, Jiaqi Zhang, Xing Guo, Wei Guo, Yaoxin Wang, Xiangning Liu, Shaoli Huang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Emerging microbes & infections, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuezhi LinState Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.
Yayu WangZhuhai Trinomab Pharmaceutical Co., Ltd, Zhuhai, People's Republic of China.
Hongxin LiState Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.
Tong LiuZhuhai Trinomab Pharmaceutical Co., Ltd, Zhuhai, People's Republic of China.
Jiaqi ZhangState Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.
Xing GuoState Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.
Wei GuoState Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.
Yaoxin WangState Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.
Xiangning LiuClinical Research Platform for Interdiscipline of Stomatology, The First Affiliated Hospital of Jinan University, Guangzhou, People's Republic of China.
Shaoli HuangThe Hong Kong University of Science and Technology, School of Engineering, Hong Kong, People's Republic of China.
Huaxin LiaoZhuhai Trinomab Pharmaceutical Co., Ltd, Zhuhai, People's Republic of China.
XiaoJun WangState Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Single B cells-based antibody platforms offer an effective approach for the discovery of useful antibodies for therapeutic or research purposes. Here we present a method for screening equine immunoglobins F(ab)2, which offers the potential advantage of reacting with multiple epitopes on the virus. Using equine influenza virus (EIV) as model, a hemagglutinin (HA) trimer was constructed to bait B cells in vaccinated horses. We screened 370 HA-specific B cells from 1 × 10

Indexed as

Antibodies, NeutralizingAntibodies, ViralB-LymphocytesOrthomyxoviridae InfectionsAnimalsCross ReactionsEpitopesFemaleHEK293 CellsHemagglutinin Glycoproteins, Influenza VirusHorsesHumansImmunoglobulin Fab FragmentsImmunologic MemoryInfluenza A Virus, H3N8 SubtypeInfluenza VaccinesAntibodies, NeutralizingAntibodies, ViralEpitopesHemagglutinin Glycoproteins, Influenza VirusImmunoglobulin Fab FragmentsInfluenza Vaccinesequine immunoglobulins F(ab)2influenza virusesneutralizing antibodiesSingle B cells-based antibody platformvaccine design

Identifiers

PMID39331815
PMCPMC11441081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.